
According to Benzinga Pro data, during Q4, AVEO Pharmaceuticals (NASDAQ:AVEO) posted sales of $17.65 million. Earnings were up 30.03%, but AVEO Pharmaceuticals still reported an overall loss of $7.25 million. AVEO Pharmaceuticals collected $15.17 million in revenue during Q3, but reported earnings showed a $10.37 million loss.